FDA grants early access to daraxonrasib for advanced pancreatic cancer

The Food and Drug Administration announced on May 1 that it will allow some patients to receive early access to daraxonrasib, an experimental treatment developed by Redwood City, California-based Revolution Medicines. The decision follows the release of late-stage clinical trial results in April that indicated a survival advantage for patients whose pancreatic cancer had spread to other parts of the body.

The FDA approved the request for an expanded access treatment protocol on April 30, just two days after the company submitted the request on April 28. This mechanism allows patients with serious or life-threatening conditions to receive experimental treatments outside of traditional clinical trials before the drug receives formal regulatory approval.

Survival gaps and the chemotherapy baseline

The FDA’s decision is informed by the statistics associated with pancreatic ductal adenocarcinoma (PDAC). According to the National Cancer Institute, more than 52,000 people are expected to die from pancreatic cancer in 2026. The disease is responsible for 8% of all cancer deaths in the U.S.

For patients with metastatic disease—cancer that has spread to distant organs—the prognosis is limited. NCI statistics show that only about 3% of these patients survive five years after their diagnosis.

The clinical trial results released by Revolution Medicines on April 13 detailed the outcomes between the experimental pill and the current standard of care. Patients taking the daily oral medication daraxonrasib lived a median of 13.2 months. In contrast, those receiving standard chemotherapy lived a median of 6.7 months.

Navigating the expanded access protocol

While the early access authorization provides a pathway for treatment, it is not a general release of the drug. The protocol is specifically for some patients who have previously been treated for pancreatic cancer and have exhausted other therapies.

For more on this story, see Blood-Based Cancer Detection: The Future of Early Diagnosis.

Under FDA rules, patients and caregivers cannot apply directly to Revolution Medicines for the drug. Instead, requests must be submitted by a licensed treating physician to ensure the protocol is followed correctly.

Revolution Medicines stated it is working to open the program as quickly as possible in the U.S. while attempting to ensure that access remains safe and equitable. The company is also pursuing a path to full approval, having sought entry into the FDA’s priority review program. The drug has already received an FDA priority review voucher, a tool designed to accelerate the development and review of medications that address unmet medical needs.

Patient impact and the limit of current data

The implications of the trial results were highlighted by former Sen. Ben Sasse, R-Nebraska. Sasse announced his pancreatic cancer diagnosis in December and later described daraxonrasib as a miracle drug for his management of the disease.

Sasse said doctors initially gave him a prognosis of three to four months but said he has more time thanks to providence, prayer, and a miracle drug. Sen. Ben Sasse, R-Nebraska

Despite the survival data, patient advocacy groups emphasize that these results are a starting point rather than a final victory. Anna Berkenblit, chief scientific and medical officer with the Pancreatic Cancer Action Network, described the study results as truly remarkable in a statement, but cautioned that the medical community must remain cautious.

This follows our earlier report, FDA Accelerates Review of Psychedelic Drugs for Mental Health with Priority Review Vouchers for Compass, Usona, and Transcend Therapeutics.

“While these results represent a huge step forward in the field, they are just the beginning,” Berkenblit said. “We know that resistance to treatment can develop, and research into drug combinations is needed to overcome these challenges.” Anna Berkenblit, Pancreatic Cancer Action Network

Berkenblit noted that more study is needed to continue progress against the deadly disease, acknowledging the reality that cancer often evolves to resist single-drug therapies.

What to watch in the regulatory pipeline

The trajectory of daraxonrasib now depends on the FDA’s priority review process. While the expanded access protocol provides immediate hope for a small subset of patients, full approval would allow the drug to be prescribed more broadly across the healthcare system.

Beyond pancreatic cancer, the pill is currently being evaluated in other late-stage trials, including research for non-small cell lung cancer. Investors have already reacted to the pancreatic trial data, with Yahoo reporting that the company’s shares rose sharply following the April announcement.

The primary focus for patients and providers over the coming months will be the rollout of the expanded access program and whether the priority review voucher leads to a shortened timeline for formal FDA approval. Until then, the drug remains experimental, and its availability is limited to those whose physicians can successfully navigate the FDA’s expanded access requirements.